John A. Fry MD, FACC, FSCAI retweeted
#CathLabHack
#CutSheathSideTubing for maintenance of #SterilePercloseSutures in the CCU with indwelling #LargeBoreAccess for #MCS of #CardiogenicShock
@realarainmd @MichaelMegalyMD @BakhshiHooman @mirvatalasnag @jedicath @agtruesdell @Allison_Dupont @Pooh_Velagapudi @AlkashkariWail @rajivxgulati @mmamas1973 @ShariqShamimMD @VladLakhter @dandu_n @NavinKapur4 @DrSethdb @DrJayMohan @jaygirimd @ziadalinyc @timir_paul @AmitGoyalMD @AmitKeswaniMD @Dr_DanMD @_backtablecards @adityadoc1 @Babar_Basir @KAlaswadMD @BaoGTran @SripalBangalore @DougDrachmanMD @mickeylev1 @drmkmittal @kevinjamescroce @KateKearney4 @RhianEDavies1
#ImpellaCP @piccoloraf @karrowni @LAzzaliniMD @DLBHATTMD @djc795 @stefan_harb @KardiologieHH @gbiondizoccai @ESHLOF @GreggWStone @DrAnkitKPatel
John A. Fry MD, FACC, FSCAI retweeted
Real-time IVUS-guided wiring for blunt-cap CTO PCI using a conventional pull-back system + dual-lumen microcatheter proved superior to angiography-guided wiring in a 152-patient study just published in CCI. #Cardiology #CTO #PCI #IVUS onlinelibrary.wiley.com/doi/… @ccijournal
Presented at #ScientificSessions26:
Among patients with cardiovascular disease and high lipoprotein(a) levels, pelacarsen lowered the lipoprotein(a) level, but the risk of major cardiovascular events was similar with pelacarsen and placebo. Full phase 3 Lp(a)HORIZON trial results: nej.md/4AcZL9n
@AHAScience

ALT A graph from the Original Article " Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).” The trial name, Lp(a)HORIZON, is in parentheses after the title. The graph shows four-component MACE in full population with lipoprotein(a) level 70 mg/dl. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.
John A. Fry MD, FACC, FSCAI retweeted
Dressler syndrome and post-cardiac injury syndrome: an autoinflammatory framework for reappraising a seventy-year-old diagnosis: a state-of-the-art review, by Yashendra Sethi et al frontiersin.org/journals/imm…
🆕2026 SCAI SHOCK Classification Expert Consensus Update
The new expert consensus update provides refined stage definitions, a greater focus on objective assessment, expanded guidance across cardiogenic shock phenotypes, and practical approaches to serial reassessment and clinical implementation.
Recognize severity. Reassess trajectory. Communicate across specialties.
Learn more ➡️ scai.org/media-center/news-a…
#SCAISHOCK #CardiogenicShock #InterventionalCardiology @SrihariNaiduMD @MyJSCAI @agtruesdell
John A. Fry MD, FACC, FSCAI retweeted
BRIGHT 4 1-year now publ in Circ CV Interv. In 6016 STEMI pts PCI w/bivalirudin vs heparin→↓death, major bleed, stent thrombosis at 30d persisting to 1 yr. Results support the class I recommendation for use of bival to reduce mortality and bleeding in the latest US guidelines.
John A. Fry MD, FACC, FSCAI retweeted
Can the risk of bailout MCS during PCI be predicted? The ORACLE Score. Presented @crfheart #TCT2026 and published simultaneously @enricopoletti4 @LAzzaliniMD @DrPrimaroNg @DrBillLombardi @BMC2_ @UWMedHeart ahajrnls.org/4edC34n
John A. Fry MD, FACC, FSCAI retweeted
Presented at #TCT2026, Paclitaxel DCBs demonstrated significantly superior drug availability in tissue through all time points. AGENT™ DCB efficiently delivers sustained arterial drug through 120 days, despite a 33-43% lower drug load vs. other PTX DCBs.
Learn more about AGENT: qrco.de/bh5BIE
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
John A. Fry MD, FACC, FSCAI retweeted
In the NODULE-SHOCK trial, researchers evaluated phenotype-specific calcium modification in patients with and without severely calcified nodules using a new-generation coronary IVL catheter.
🔎 Explore the trial findings: bit.ly/4iRU2jh
#TCT2026 #JACCINT @crfheart
John A. Fry MD, FACC, FSCAI retweeted
IABP vs Impella for LV Unloading in VA-ECMO. Supply: demand improved with IABP but not Impella. Presented @crfheart #TCT2026 and published simultaneously @SaadEzad @divaka_perera @UKheartresearch @VPanoulas @PBSherren @K_DeSilva @DrMattRyan @hollymorgs ahajrnls.org/4icUqZy
John A. Fry MD, FACC, FSCAI retweeted
In the FRACTURE study (n=420), a quad-emitter IVL system showed safety (30-day freedom from MACE 93.3%) & efficacy (procedural success 93.7%) in modifying severe calcified coronary lesions & facilitating stent implantation.
#JACCINT #PCI
bit.ly/4yPvqwi
John A. Fry MD, FACC, FSCAI retweeted
RADIAL PCI: NOT ALL HEMATOMAS ARE THE SAME
After transradial or transulnar PCI, a forearm hematoma should be recognized early and classified by how far it extends.
The classic EASY classification:
⬜ Grade I: local, superficial hematoma, ≤5 cm
🟧 Grade II: ≤10 cm with moderate muscular infiltration
🟩 Grade III: extends beyond the elbow with muscular infiltration
🟥 Grade IV: extends above the elbow
🟦 Grade V: signs of ischemia/compartment syndrome
The practical lesson:
1️⃣ Small hematoma: observe and compress.
2️⃣ Expanding hematoma: escalate compression and reassess frequently.
3️⃣ Extensive hematoma: urgent physician assessment.
4️⃣ Ischemic/compartment syndrome: emergency management.
Check the hand perfusion, pulses, sensation, motor function, pain and progression of swelling rather than judging severity by size alone.
Radial access remains preferred for PCI in ACS because it reduces bleeding and vascular complications compared with femoral access.
Reference: Bertrand OF et al. EASY hematoma classification; updated context from ACC/AHA/SCAI revascularization and ACS guidance.
John A. Fry MD, FACC, FSCAI retweeted
Not an infrequent question for cardiologists from psychiatrists & patients; nice article here @bmj_latest bmj.com/content/394/bmj-2026…
John A. Fry MD, FACC, FSCAI retweeted
Anyone doing this- prolonged balloon inflation during STEMI
“primary PCI assigned 1:1 to POP (stent inflation to ≥14 atm maintained until pressure stability, defined as no pressure drop ≥0.3 atm over 30 seconds) or conventional rapid inflation–deflation stenting”
#CardioX
John A. Fry MD, FACC, FSCAI retweeted
International Day for Interventional Cardiology: the first coronary #angioplasty
On 16 September 1977, Andreas Grüntzig & his team made history, and changed the lives of millions of patients forever.
Standing on the shoulders of the giants that came before him, this transformative vision led to an entirely new field of medicine.
What began nearly five decades ago with coronary angioplasty has grown into the broad field of interventional cardiology, transforming cardiovascular care through research, innovation and technological progress.
As the field has evolved, so has the need to learn from experience, share knowledge and shape what comes next. Join us in 2027 at #EuroPCR to mark this landmark moment!
📅pcronline.com/Courses/EuroPC…
#medicalhistory #interventionalcardiologist #cathlab #cathlabteam
@NievesGonzalo1 @CuissetDr @nicolasdumonte1 @EmanueleBarba13
John A. Fry MD, FACC, FSCAI retweeted
Tomorrow's the 49th anniversary of Andreas Gruentzig doing the 1st coronary angioplasty. Watch this extended version of the story, told by those who were there: Adolph Bachmann (1st patient) Bernhard Meier (his doctor) & Maria Schlumpf (Gruentzig's assistant). Next year's the 50th: surprises coming! #AngioHistory
John A. Fry MD, FACC, FSCAI retweeted
🧵 New @JACCJournals study from #CHIP-BCIS3 provides an important physiologic look at #Impella-supported high-risk #PCI—and challenges how we think about “protected PCI.”
The key message: hemodynamic support ≠ myocardial protection.
1/6
John A. Fry MD, FACC, FSCAI retweeted
In PICCOLETO X study, in pts undergoing CTO #PCI, a DCB-based strategy, either alone or in combination with stents, had favorable 1yr clinical outcomes. No significant differences between DCB-only & blended treatment with a stent jacc.org/doi/10.1016/j.jcin.… #JACCINT @Bhcintervention




































